ArticleClinical, cosmetic and investigational dermatology2025
Managing Atopic Dermatitis with Dupilumab in Special Populations: A Case Series Study.
Article in Clinical, cosmetic and investigational dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ultra-High-Frequency Ultrasound of Melanoma Excision Scars for Detection of Clinically Occult Local Recurrence: A Single-Center Retrospective Study.Clinical, cosmetic and investigational dermatology · 2026Article
- Advanced Cutaneous Squamous Cell Carcinoma: Biology, Immunotherapy, and Evolving Prognostic Factors.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disorder with skin barrier disruptions and heightened T helper (Th) 2-mediated inflammation. Dupilumab, a monoclonal antibody targeting interleukin-4 and -13 pathways, has shown efficacy in treating AD and other type 2 inflammatory diseases. However, its safety and effectiveness in special populations (SP) like kidney transplant recipients, cancer patients, and individuals with neurological conditions remain unclear. Materials and Methods: This retrospective case series includes 12 representative cases of SP treated with dupilumab, featuring cases of a kidney transplant recipient, a metastatic melanoma patient, a non-functioning pituitary adenoma patient, and an individual with multiple sclerosis (MS). Clinical data were collected, and outcomes were assessed using various indices. Results: Dupilumab provided significant AD symptom improvement across all cases, with no adverse effects or recurrence of underlying conditions. Conclusion: Dupilumab shows promise for managing AD in SP, but careful monitoring and further research are necessary to address safety concerns and optimize treatment strategies. Larger studies with longer follow-ups are needed to fully evaluate its safety and efficacy in SP and those with comorbidities. These findings support the need for personalized treatments and ongoing research to enhance outcomes in patients with complex medical histories.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.